BioTime Company Profile (NYSEMKT:BTX)

About BioTime

BioTime logoBioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company's pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient's own somatic or adult stem cells, at the desired location.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NYSEMKT
  • Symbol: BTX
  • CUSIP: 09066L10
Key Metrics:
  • Previous Close: $2.97
  • 50 Day Moving Average: $3.23
  • 200 Day Moving Average: $3.37
  • 52-Week Range: $2.15 - $4.01
  • Trailing P/E Ratio: 12.09
  • Foreward P/E Ratio: -7.76
  • P/E Growth: 0.00
  • Market Cap: $326.81M
  • Outstanding Shares: 102,772,000
  • Beta: 1.37
Additional Links:
Companies Related to BioTime:

Analyst Ratings

Consensus Ratings for BioTime (NYSEMKT:BTX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00

Analysts' Ratings History for BioTime (NYSEMKT:BTX)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$6.00View Rating Details
4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details
4/2/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for BioTime (NYSEMKT:BTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017        
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/9/2016Q4($0.17)($0.16)ViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)ViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioTime (NYSEMKT:BTX)
Current Year EPS Consensus Estimate: $0.24 EPS
Next Year EPS Consensus Estimate: $-0.41 EPS

Dividends

Dividend History for BioTime (NYSEMKT:BTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioTime (NYSEMKT:BTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.00View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.00View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.00View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioTime (NYSEMKT:BTX)
DateHeadline
marketexclusive.com logoBioTime, Inc. (NYSEMKT:BTX) Files An 8-K Completion of Acquisition or Disposition of Assets (NYSEMKT:BTX)
marketexclusive.com - February 21 at 6:10 PM
News IconStock Scrambling Higher Mid-Afternoon: BioTime, Inc.(:BTX) - Aiken Advocate (NYSEMKT:BTX)
aikenadvocate.com - February 21 at 1:09 PM
streetinsider.com logoBioTime (BTX) Reports Deconsolidation of OncoCyte Inc.'s Financial ... - StreetInsider.com (NYSEMKT:BTX)
www.streetinsider.com - February 21 at 1:09 PM
News IconTechnicals in View on This Stock: BioTime, Inc. (AMEX:BTX) - BVN (NYSEMKT:BTX)
bvnewsjournal.com - February 18 at 10:04 AM
us.rd.yahoo.com logoCORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh (NYSEMKT:BTX)
us.rd.yahoo.com - February 16 at 9:08 PM
us.rd.yahoo.com logoBioTime, Inc. Announces Closing of Public Offering of Common Stock (NYSEMKT:BTX)
us.rd.yahoo.com - February 16 at 9:08 PM
News IconSell-Side Analysts Taking Aim at BioTime, Inc. (:BTX) Telephone and Data Systems, Inc. (NYSE:TDS) - Davidson Register (NYSEMKT:BTX)
davidsonregister.com - February 16 at 4:08 PM
News IconTechnical Levels in Review on Shares of BioTime Inc. (BTX) - Baxter Review (NYSEMKT:BTX)
baxternewsreview.com - February 16 at 4:08 PM
finance.yahoo.com logoCORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for ... - Yahoo Finance (NYSEMKT:BTX)
finance.yahoo.com - February 16 at 8:53 AM
4-traders.com logoBioTime : to Present at Two Upcoming Investor Conferences (NYSEMKT:BTX)
www.4-traders.com - February 14 at 2:37 AM
biz.yahoo.com logoBIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NYSEMKT:BTX)
us.rd.yahoo.com - February 14 at 2:37 AM
News IconInvesting Focus: Indicators in View on Shares of BioTime Inc. (BTX) - Rives Journal (NYSEMKT:BTX)
rivesjournal.com - February 13 at 9:36 PM
News IconInvestor's Alert Endo International plc – Ordinary Shares (NASDAQ:ENDP), BioTime, Inc. (NYSEMKT:BTX) - Financial Breaking News (NYSEMKT:BTX)
wsbreakingnews.com - February 13 at 9:36 PM
News IconStocks Movement Analysis: BioTime, Inc. (NYSEMKT:BTX), Grupo Televisa, SAB (NYSE:TV) - The Newburgh Press (NYSEMKT:BTX)
newburghpress.com - February 13 at 4:36 PM
News IconNews Highlights- BioTime, Inc. (NYSE:BTX), General Electric (NYSE:GE), Catalyst Biosciences (NASDAQ:CBIO) - Street Wise Report (press release) (blog) (NYSEMKT:BTX)
streetwisereport.com - February 13 at 4:36 PM
News IconStock Jolted Higher in Mid-day Trade: BioTime, Inc. (:BTX) - Aiken Advocate (NYSEMKT:BTX)
aikenadvocate.com - February 13 at 4:36 PM
News IconFanning the Flames: Increased Volatility Noted on Shares of BioTime, Inc. (:BTX) - Aiken Advocate (NYSEMKT:BTX)
aikenadvocate.com - February 13 at 4:36 PM
News IconExelixis, Inc. (NASDAQ:EXEL)- Stocks Hammered on Sluggish Data: BioTime, Inc. (NYSE:BTX) - Street Wise Report (press release) (blog) (NYSEMKT:BTX)
streetwisereport.com - February 13 at 2:11 AM
streetinsider.com logoBioTime (BTX) Prices 6.5M Common Stock Offering at $2.70/Share (NYSEMKT:BTX)
www.streetinsider.com - February 11 at 4:08 PM
investopedia.com logoBioTime Launches $17 Million Public Offering (BTX) (NYSEMKT:BTX)
www.investopedia.com - February 11 at 4:08 PM
us.rd.yahoo.com logoBioTime, Inc. Announces Pricing of Public Offering of Common Stock (NYSEMKT:BTX)
us.rd.yahoo.com - February 11 at 4:08 PM
News IconStock Spotter: Review on Technical Levels for BioTime Inc. (BTX) - Davidson Register (NYSEMKT:BTX)
davidsonregister.com - February 10 at 8:37 PM
streetinsider.com logoBioTime (BTX) Prices 6.5M Common Stock Offering at $2.70/Share - StreetInsider.com (NYSEMKT:BTX)
www.streetinsider.com - February 10 at 3:37 PM
investopedia.com logoBioTime Declares $17.5M Public Stock Offering (NYSEMKT:BTX)
www.investopedia.com - February 10 at 3:37 PM
streetinsider.com logoBioTime (BTX) Plans Offer of Common Stock (NYSEMKT:BTX)
www.streetinsider.com - February 10 at 2:25 AM
us.rd.yahoo.com logo4:01 pm BioTime commences common stock offering; size not disclosed (NYSEMKT:BTX)
us.rd.yahoo.com - February 9 at 9:22 PM
thestreet.com logoAcorda, Amgen and Regeneron Lead Premarket Biotech Movers (NYSEMKT:BTX)
www.thestreet.com - February 9 at 4:20 PM
finance.yahoo.com logoBioTime, Inc. Announces Proposed Public Offering of Common Stock (NYSEMKT:BTX)
finance.yahoo.com - February 9 at 4:20 PM
biz.yahoo.com logoBIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NYSEMKT:BTX)
biz.yahoo.com - February 9 at 4:20 PM
businesswire.com logoBioTime Appoints Industry Veteran, Stephana Patton, Ph.D., JD, as General Counsel - Business Wire (press release) (NYSEMKT:BTX)
www.businesswire.com - February 9 at 2:23 AM
streetinsider.com logoBioTime (BTX) Announces Acquisition of Global Rights to Ophthalmology-Related IP Assets From UPMC (NYSEMKT:BTX)
www.streetinsider.com - February 8 at 3:13 AM
finance.yahoo.com logoBioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel (NYSEMKT:BTX)
finance.yahoo.com - February 7 at 5:08 PM
streetinsider.com logoBioTime (BTX) Announces Acquisition of Global Rights to Ophthalmology-Related IP Assets From UPMC - StreetInsider.com (NYSEMKT:BTX)
www.streetinsider.com - February 6 at 9:06 PM
tmcnet.com logoBioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of … (NYSEMKT:BTX)
www.tmcnet.com - February 6 at 4:05 PM
finance.yahoo.com logoBioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center (NYSEMKT:BTX)
finance.yahoo.com - February 6 at 4:05 PM
finance.yahoo.com logo7:02 am BioTime acquires global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh's Medical Center; terms not disclosed (NYSEMKT:BTX)
finance.yahoo.com - February 6 at 4:05 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of BioTime, Inc. (NYSEMKT:BTX)
finance.yahoo.com - January 30 at 9:04 PM
News IconInvestor Focus: Watching Shares of BioTime, Inc. (AMEX:BTX) - The Tribune (NYSEMKT:BTX)
lakecitytribune.com - January 30 at 4:03 PM
News IconInvestor Technical Review for BioTime Inc. (BTX) - Rives Journal (NYSEMKT:BTX)
rivesjournal.com - January 30 at 2:03 AM
News IconWatching the Numbers for BioTime, Inc. (AMEX:BTX) - Gilbert Daily (NYSEMKT:BTX)
gilbertdaily.com - January 30 at 2:03 AM
tmcnet.com logoBioTime to Present at Noble Capital Markets' Thirteenth Annual Investor Conference (NYSEMKT:BTX)
www.tmcnet.com - January 28 at 4:07 PM
News IconFollowing the Numbers on Shares of BioTime, Inc. (AMEX:BTX ... - The Tribune (NYSEMKT:BTX)
lakecitytribune.com - January 27 at 10:09 PM
News IconTrading Spotlight: Zooming in on Shares of BioTime Inc. (BTX) - Sherwood Daily (NYSEMKT:BTX)
sherwooddaily.com - January 26 at 4:52 PM
finance.yahoo.com logoBioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference (NYSEMKT:BTX)
finance.yahoo.com - January 26 at 4:52 PM
News IconTicker Watch: Technical Views on Shares of BioTime Inc. (BTX) - Sherwood Daily (NYSEMKT:BTX)
sherwooddaily.com - January 25 at 2:39 AM
seekingalpha.com logoAsterias Has Strong Upside Potential In 2017 (NYSEMKT:BTX)
seekingalpha.com - January 24 at 4:36 PM
News IconValue Composite Score Update on BioTime, Inc. (AMEX:BTX) - The Tribune (NYSEMKT:BTX)
lakecitytribune.com - January 23 at 4:20 PM
News IconStock Backsliding Ahead of the Bell: BioTime, Inc. (:BTX) - Aiken Advocate (NYSEMKT:BTX)
aikenadvocate.com - January 23 at 4:20 PM
News IconChart Trading: Viewing CCI and ADX Levels for BioTime Inc. (BTX) - Sherwood Daily (NYSEMKT:BTX)
sherwooddaily.com - January 22 at 4:02 PM
News IconEquity Research Analysts Peer Into Their Crystal Ball For BioTime, Inc. (:BTX) - Aiken Advocate (NYSEMKT:BTX)
aikenadvocate.com - January 21 at 9:04 PM

Social

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "BTX."

Where is BioTime's stock going? Where will BioTime's stock price be in 2017?

3 brokers have issued 12-month target prices for BioTime's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate BioTime's stock price to reach $6.00 in the next twelve months.

When will BioTime announce their earnings?

BioTime is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.

Who owns BioTime stock?

BioTime's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.02%), Two Sigma Investments LP (0.06%), Metropolitan Life Insurance Co. NY (0.05%), Intellectus Partners LLC (0.03%) and Guggenheim Capital LLC (0.03%). Company insiders that own BioTime stock include Alfred D Kingsley, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Stephen C Farrell and Stephen Lahue Cartt.

Who sold BioTime stock? Who is selling BioTime stock?

BioTime's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY.

Who bought BioTime stock? Who is buying BioTime stock?

BioTime's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Intellectus Partners LLC, Two Sigma Investments LP and Guggenheim Capital LLC. Company insiders that have bought BioTime stock in the last two years include Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Stephen C Farrell and Stephen Lahue Cartt.

How do I buy BioTime stock?

Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioTime stock cost?

One share of BioTime stock can currently be purchased for approximately $3.18.


Last Updated on 2/22/2017 by MarketBeat.com Staff